# A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

> **NCT06511739** · PHASE2 · RECRUITING · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Non-segmental Vitiligo

## Interventions

- **DRUG:** SYHX1901
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06511739
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-27
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2024-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511739, "A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06511739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*